Clinical Trial Update: Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT. [Phase 2]

View source ↗

Summary

Phase II trial evaluating PF-299804 (dacomitinib), a Pan-HER irreversible inhibitor, in recurrent glioblastoma with EGFR amplification or EGFRvIII mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• PF-299804 (dacomitinib) (dacomitinib)

Snippet

Sponsor: Grupo Español de Investigación en Neurooncología | Conditions: Glioblastoma, Brain Tumor, Recurrent | Phase 2 | Status: COMPLETED | Results posted: 2021-07-06